Serious hyponatremia in patients with cancer: management with demeclocycline.
Seventeen patients with cancer or aplastic anemia received demeclocycline as treatment for hyponatremia. Prior to demeclocycline therapy no patients showed clinical signs of fluid overload or saline depletion. In all patients inappropriately concentrated urine (mean urine osmolality = 548 mOSM/kg H2O) or increased urine content of sodium (mean urine sodium = 91 mEq/L) were documented prior to demeclocycline therapy. No patient had developed hyponatremia in association with antineoplastic drug therapy. The average serum sodium (NaS) at the time of initiation of therapy was 121 mEq/L. NaS increased in all patients despite the simultaneous administration of generous volumes of fluid. NaS exceeded 130 mEq/L and average of 3.5 days following institution of demeclocycline. Patients lost an average of 2.3 kg during demeclocycline. The toxicity noted following demeclocycline was azotemia and increased serum creatinine. Eight patients developed serum urea nitrogen (SUN) in excess of 25 mg/dl; average maximum creatinine in these eight patients was 1.9 mg/dl. Average peak creatinine in eight patients who did not develop azotemia was 0.87 mg/dl. Azotemia seemed to be correlated with simultaneous administration of other nephrotoxic agents and with administration of higher doses (1200 mg/day) of demeclocycline.
D003404:Creatinine / Q000097:blood; D003707:Demeclocycline / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007010:Hyponatremia / Q000150:complications / Q000188:drug therapy*; D009369:Neoplasms / Q000150:complications*; D009994:Osmolar Concentration; D014511:Uremia / Q000139:chemically induced; D014869:Water Intoxication / Q000150:complications / Q000188:drug therapy
D003707:Demeclocycline; D003404:Creatinine